GlassScriptPhysician profile
Peiyun Chu
NPI 1467520536
$10,230.58
in general payments reported to CMS, 2019-2025
52 companies · $1,794 in 2025
The $1,794 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,103 · 2020: $1,329 · 2021: $1,171 · 2022: $3,219 · 2023: $650 · 2024: $964 · 2025: $1,794.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,408.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,407.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,434.43 | 2019-2025 | Ubrelvy, Botox, Duopa |
| Medtronic, INC. | $1,316.40 | 2021-2025 | Percept PC Brainsense |
| Novartis Pharmaceuticals Corporation | $871.32 | 2019-2025 | |
| Amgen INC. | $649.00 | 2019-2022 | |
| Pfizer INC. | $586.48 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $492.54 | 2019-2022 | |
| Eisai INC. | $488.26 | 2020-2025 | |
| Neurocrine Biosciences, INC. | $414.76 | 2019-2022 | |
| Genzyme Corporation | $376.67 | 2019-2022 | |
| Mdd US Operations, LLC | $243.30 | 2019-2025 | Gocovri |
| Lundbeck LLC | $233.93 | 2020-2025 | Vyepti, Rexulti |
| Biogen, INC. | $221.76 | 2020-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $218.00 | 2022 | |
| Sk Life Science, INC. | $205.48 | 2020-2024 | |
| Alexion Pharmaceuticals, INC. | $201.97 | 2019-2021 |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peiyun Chu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.